At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLRX Salarius Pharmaceuticals Inc
Trading 01-02 11:47:28 EST
0.6541
+0.0053
+0.82%
High0.6679Low0.6411Vol23.50K
Open0.6488D1 Closing0.6488Amplitude4.13%
Mkt Cap3.83MTradable Cap2.33MTotal Shares5.86M
T/O15.51KT/O Rate0.66%Tradable Shares3.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Dow Jones  ·  2025-12-20
Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics
Reuters  ·  2025-12-18
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
THOMSON REUTERS  ·  2025-12-18
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing
MT Newswires Live  ·  2025-12-01
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing
BRIEF-Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study
Reuters  ·  2025-12-01
BRIEF-Salarius Pharmaceuticals To Collaborate With Texas Biomedical Research Institute On Avian Flu Study
Salarius Pharmaceuticals to Collaborate With Texas Biomedical Research Institute on Avian Flu Study
THOMSON REUTERS  ·  2025-12-01
Salarius Pharmaceuticals to Collaborate With Texas Biomedical Research Institute on Avian Flu Study
Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares
Reuters  ·  2025-11-25
Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce
Reuters  ·  2025-11-25
Salarius Pharmaceuticals Files Initial Beneficial Ownership Statement for CEO Frederick II Pierce
Salarius Pharmaceuticals CFO Mark J. Rosenblum Acquires Common Shares
Reuters  ·  2025-11-21
Salarius Pharmaceuticals CFO Mark J. Rosenblum Acquires Common Shares
BRIEF-Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - Filing
Reuters  ·  2025-11-20
BRIEF-Salarius Pharmaceuticals Inc - Frederick E. Pierce To Serve As Chief Executive Officer - Filing
Salarius Pharmaceuticals Inc - Frederick E. Pierce to Serve as Chief Executive Officer - Filing
THOMSON REUTERS  ·  2025-11-20
Salarius Pharmaceuticals Inc - Frederick E. Pierce to Serve as Chief Executive Officer - Filing
Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million
Reuters  ·  2025-11-20
Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics and Raises $8 Million
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
GlobeNewswire  ·  2025-11-20
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Salarius Pharmaceuticals - Became Aware That Certain Financial Market Data Platforms Published That Co Had Been Delisted From Nasdaq
THOMSON REUTERS  ·  2025-11-18
Salarius Pharmaceuticals - Became Aware That Certain Financial Market Data Platforms Published That Co Had Been Delisted From Nasdaq
BUZZ-Salarius jumps after completing merger with Decoy Therapeutics
Reuters  ·  2025-11-13
BUZZ-Salarius jumps after completing merger with Decoy Therapeutics
Press Release: Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Dow Jones  ·  2025-11-13
Press Release: Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Crude Oil Dips 4%; On Holding Shares Jump After Q3 Earnings
Benzinga  ·  2025-11-13
Crude Oil Dips 4%; On Holding Shares Jump After Q3 Earnings
Shoulder Innovations (SI) Stock Rose 21% After-Hours: Here's Why
Benzinga  ·  2025-11-12
Shoulder Innovations (SI) Stock Rose 21% After-Hours: Here's Why
Why Did RYTHM (RYM) Stock Jump Over 23% Overnight?
Benzinga  ·  2025-11-12
Why Did RYTHM (RYM) Stock Jump Over 23% Overnight?
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?
Benzinga  ·  2025-11-12
Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Introduction

Company Name.
Salarius Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
Issue price:
--